Möchten Sie immer auf dem neuesten Stand bleiben?

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO...

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are...

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors...

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Italy marked a significant presence at PDAC 2026, the world’s premier mining & exploration convention, showcasing the height of "Made in Italy" technology.

Immuneering to Present at the Leerink Global Healthcare Conference

Jim Coates appointment full-time permanent CEO

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference